U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07077486) titled 'Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease' on Dec. 30, 2023.
Brief Summary: Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and clinical ILD in patients with early lupus.
Study Start Date: July 25
Study Type: INTERVENTIONAL
Condition:
Lupus or SLE
Interstitial Lung Disease
Systemic Lupus Erythematosus
Intervention:
DRUG: Methylprednisolone (Corticosteroid)
In addition to conventional treatment (methyl-40mg or less...